Literature DB >> 35877180

Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice.

Teayoun Kim1, Shelly Nason1, Jessica Antipenko1, Brian Finan2, Anath Shalev1, Richard DiMarchi3, Kirk M Habegger1.   

Abstract

Long-term glucagon receptor (GCGR) agonism is associated with hyperglycemia and glucose intolerance, while acute GCGR agonism enhances whole-body insulin sensitivity and hepatic AKTSer473 phosphorylation. These divergent effects establish a critical gap in knowledge surrounding GCGR action. mTOR complex 2 (mTORC2) is composed of seven proteins, including RICTOR, which dictates substrate binding and allows for targeting of AKTSer473. We used a liver-specific Rictor knockout mouse (RictorΔLiver) to investigate whether mTORC2 is necessary for insulin receptor (INSR) and GCGR cross talk. RictorΔLiver mice were characterized by impaired AKT signaling and glucose intolerance. Intriguingly, RictorΔLiver mice were also resistant to GCGR-stimulated hyperglycemia. Consistent with our prior report, GCGR agonism increased glucose infusion rate and suppressed hepatic glucose production during hyperinsulinemic-euglycemic clamp of control animals. However, these benefits to insulin sensitivity were ablated in RictorΔLiver mice. We observed diminished AKTSer473 and GSK3α/βSer21/9 phosphorylation in RictorΔLiver mice, whereas phosphorylation of AKTThr308 was unaltered in livers from clamped mice. These signaling effects were replicated in primary hepatocytes isolated from RictorΔLiver and littermate control mice, confirming cell-autonomous cross talk between GCGR and INSR pathways. In summary, our study reveals the necessity of RICTOR, and thus mTORC2, in GCGR-mediated enhancement of liver and whole-body insulin action.
© 2022 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35877180      PMCID: PMC9501720          DOI: 10.2337/db21-1018

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.337


  36 in total

1.  Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c.

Authors:  Asami Hagiwara; Marion Cornu; Nadine Cybulski; Pazit Polak; Charles Betz; Francesca Trapani; Luigi Terracciano; Markus H Heim; Markus A Rüegg; Michael N Hall
Journal:  Cell Metab       Date:  2012-04-19       Impact factor: 27.287

2.  Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2.

Authors:  Minsheng Yuan; Elizabeth Pino; Lianfeng Wu; Michael Kacergis; Alexander A Soukas
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

3.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

4.  Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta).

Authors:  H Cho; J Mu; J K Kim; J L Thorvaldsen; Q Chu; E B Crenshaw; K H Kaestner; M S Bartolomei; G I Shulman; M J Birnbaum
Journal:  Science       Date:  2001-06-01       Impact factor: 47.728

5.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

Authors:  Jonathan W Day; Nickki Ottaway; James T Patterson; Vasily Gelfanov; David Smiley; Jas Gidda; Hannes Findeisen; Dennis Bruemmer; Daniel J Drucker; Nilika Chaudhary; Jenna Holland; Jazzminn Hembree; William Abplanalp; Erin Grant; Jennifer Ruehl; Hilary Wilson; Henriette Kirchner; Sarah Haas Lockie; Susanna Hofmann; Stephen C Woods; Ruben Nogueiras; Paul T Pfluger; Diego Perez-Tilve; Richard DiMarchi; Matthias H Tschöp
Journal:  Nat Chem Biol       Date:  2009-07-13       Impact factor: 15.040

Review 6.  mTOR at the nexus of nutrition, growth, ageing and disease.

Authors:  Grace Y Liu; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2020-01-14       Impact factor: 94.444

7.  Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Mahmoud M Ali; Ahmed Hafez; Mahmoud Shaban Abdelgalil; Mohammed Tarek Hasan; Mohammed Magdy El-Ghannam; Osama M Ghogar; Asmaa Ahmed Elrashedy; Mohamed Abd-ElGawad
Journal:  BMC Endocr Disord       Date:  2022-04-29       Impact factor: 3.263

8.  Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.

Authors:  Victoria E R Parker; Thuong Hoang; Heike Schlichthaar; Fraser W Gibb; Barbara Wenzel; Maximillian G Posch; Ludger Rose; Yi-Ting Chang; Marcella Petrone; Lars Hansen; Philip Ambery; Lutz Jermutus; Hiddo J L Heerspink; Rory J McCrimmon
Journal:  Diabetes Obes Metab       Date:  2022-04-25       Impact factor: 6.408

9.  Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism.

Authors:  Yuefeng Tang; Martina Wallace; Joan Sanchez-Gurmaches; Wen-Yu Hsiao; Huawei Li; Peter L Lee; Santiago Vernia; Christian M Metallo; David A Guertin
Journal:  Nat Commun       Date:  2016-04-21       Impact factor: 14.919

10.  Twenty-five years of mTOR: Uncovering the link from nutrients to growth.

Authors:  David M Sabatini
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.